Voyager Therapeutics Future Growth
Future criteria checks 0/6
Voyager Therapeutics's revenue and earnings are forecast to decline at 40.4% and 40.3% per annum respectively. EPS is expected to decline by 40.2% per annum. Return on equity is forecast to be -27.3% in 3 years.
Key information
-40.3%
Earnings growth rate
-40.2%
EPS growth rate
Biotechs earnings growth | 24.5% |
Revenue growth rate | -40.4% |
Future return on equity | -27.3% |
Analyst coverage | Good |
Last updated | 30 Apr 2024 |
Recent future growth updates
Recent updates
There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise
Mar 15Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier
Mar 08What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates
Mar 04Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement
Jan 04Voyager stock rises as Pfizer opts to use AAV capsid for neurologic disease target
Oct 04Voyager Therapeutics hires new finance chief
Sep 07Voyager Therapeutics GAAP EPS of -$0.50 misses by $0.02
Aug 04Looking Back In On Voyager Therapeutics
Jun 08Need To Know: Analysts Just Made A Substantial Cut To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates
May 12Voyager Does A Reboot After First Generation Failures
Mar 25Companies Like Voyager Therapeutics (NASDAQ:VYGR) Could Be Quite Risky
Feb 07Voyager Therapeutics: Another Year, Another Deal
Nov 21Some Analysts Just Cut Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates
Aug 11Newsflash: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Analysts Have Been Trimming Their Revenue Forecasts
Jul 18Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 55 | -108 | -88 | -81 | 7 |
12/31/2025 | 51 | -106 | -64 | -59 | 10 |
12/31/2024 | 39 | -98 | -66 | -61 | 10 |
12/31/2023 | 250 | 132 | 75 | 78 | N/A |
9/30/2023 | 158 | 52 | 86 | 89 | N/A |
6/30/2023 | 195 | 96 | 91 | 94 | N/A |
3/31/2023 | 191 | 99 | 74 | 77 | N/A |
12/31/2022 | 41 | -46 | -15 | -13 | N/A |
9/30/2022 | 71 | -17 | 9 | 11 | N/A |
6/30/2022 | 31 | -60 | 4 | 6 | N/A |
3/31/2022 | 32 | -71 | 1 | 2 | N/A |
12/31/2021 | 37 | -71 | -55 | -54 | N/A |
9/30/2021 | 16 | -93 | -92 | -87 | N/A |
6/30/2021 | 132 | 18 | -100 | -91 | N/A |
3/31/2021 | 160 | 39 | -100 | -89 | N/A |
12/31/2020 | 171 | 37 | -109 | -97 | N/A |
9/30/2020 | 197 | 40 | -110 | -98 | N/A |
6/30/2020 | 100 | -61 | -103 | -95 | N/A |
3/31/2020 | 117 | -41 | -113 | -105 | N/A |
12/31/2019 | 104 | -44 | 41 | 49 | N/A |
9/30/2019 | 74 | -54 | 43 | 48 | N/A |
6/30/2019 | 55 | -59 | 47 | 52 | N/A |
3/31/2019 | 12 | -96 | 57 | 61 | N/A |
12/31/2018 | 8 | -88 | -20 | -16 | N/A |
9/30/2018 | 12 | -78 | -10 | -6 | N/A |
6/30/2018 | 11 | -81 | -8 | -5 | N/A |
3/31/2018 | 10 | -74 | -1 | 2 | N/A |
12/31/2017 | 10 | -71 | -65 | -61 | N/A |
9/30/2017 | 6 | -74 | N/A | -60 | N/A |
6/30/2017 | 8 | -59 | N/A | -54 | N/A |
3/31/2017 | 11 | -50 | N/A | -47 | N/A |
12/31/2016 | 14 | -40 | N/A | -42 | N/A |
9/30/2016 | 17 | -34 | N/A | -39 | N/A |
6/30/2016 | 18 | -32 | N/A | -36 | N/A |
3/31/2016 | 20 | -30 | N/A | -33 | N/A |
12/31/2015 | 17 | -38 | N/A | 41 | N/A |
9/30/2015 | 12 | -35 | N/A | 46 | N/A |
6/30/2015 | 7 | -32 | N/A | 50 | N/A |
3/31/2015 | 3 | -30 | N/A | 55 | N/A |
12/31/2014 | N/A | -18 | N/A | -12 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VYGR's earnings are forecast to decline over the next 3 years (-40.3% per year).
Earnings vs Market: VYGR's earnings are forecast to decline over the next 3 years (-40.3% per year).
High Growth Earnings: VYGR's earnings are forecast to decline over the next 3 years.
Revenue vs Market: VYGR's revenue is expected to decline over the next 3 years (-40.4% per year).
High Growth Revenue: VYGR's revenue is forecast to decline over the next 3 years (-40.4% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: VYGR is forecast to be unprofitable in 3 years.